Portfolio
Circularis
(Acquired by Gingko Bioworks)
“Circularis controls the path to make the desired amount of protein in locations of interests. In manufacturing the goal most often is to make the most protein possible, while in gene therapy it is to express a very specific amount in a very specific subset of cells, while providing a therapeutic benefit. Circularis uses circular RNA as a reporter assay to tell what is happening in millions of cells in one tube. We read out the data with next-generation sequencing and then de-convolute it to identify DNA elements that create the protein expression profiles customers need.”
Team: Mat Falkowski, Paul Feldstein, & LeAnn Lindsay
Location: Oakland, California
Category: Life Sciences / Services / Gene Therapy
Company Stage: Seed
Co-Investors: KdT Ventures, Cantos, amongst others
